CRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Salesforce (CRM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price declines and bearish technical indicators, the stock's valuation is compelling, supported by strong cash flow, a significant stock buyback program, and growth in AI-driven revenue. Positive sentiment from Congress trading data and an analyst upgrade with a $200 price target further strengthen the case for investment.
The technical indicators suggest a bearish trend with MACD negatively expanding, RSI at an oversold level of 13.368, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support is at 153.784, with resistance at 186.415. While the stock is oversold, it may present a long-term buying opportunity.
Congress trading data shows heavy buying with $4.6M to $16.5M in purchase transactions.
AI-driven revenue growth of 200% YoY, generating $3.4 billion in annual recurring revenue.
Strong free cash flow of $6.6 billion in Q1 FY
A $25 billion stock buyback reducing share count by 10%.
Analyst upgrade by Monness Crespi with a $200 price target, citing compelling valuation and strong cash flow.
Recent price decline of -2.09% in the regular market and -1.45% in pre-market trading.
Bearish technical indicators with oversold RSI and negative MACD.
Analyst downgrades and reduced price targets from multiple firms, reflecting concerns about decelerating growth and weaker guidance.
Limited evidence of immediate revenue growth acceleration, as noted by analysts.
Salesforce reported $6.6 billion in free cash flow for Q1 FY27 and executed a $25 billion stock buyback. While revenue growth has been weak for two years, the company has focused on cost controls and expects growth acceleration in the second half of FY27. AI and data products are driving significant revenue growth.
Analysts are mixed on Salesforce. Monness Crespi upgraded the stock to Buy with a $200 price target, citing compelling valuation and strong cash flow. However, other analysts have lowered price targets, reflecting concerns about decelerating growth and weaker guidance. The consensus leans towards cautious optimism, with several Buy ratings and reduced price targets.
